Bodisen Biotech Received Contracts
Totaling $27.4 Million in January for 2005 Product
Wednesday February 9,
9:00 am ET
NEW YORK--(BUSINESS WIRE)--Feb. 9, 2005--Bodisen Biotech, Inc.,
(OTCBB: BBOI, website: /)
announced today that in January its total contracts received for
2005 product delivery totaled $27.4 million. This figure does not
include any contracts that are likely to be secured in the remaining
three quarters of 2005. Bodisen's new customers include a number of
large national wholesale distributors that were secured at recent
expos, tradeshows and by Bodisen's growing brand name.
Ms. Qiong Wang, CEO of Bodisen, commented "We are very pleased
with the new contracts that we have obtained for 2005 delivery. We
are now nearing the completion of our new manufacturing facilities
which will at least double our current manufacturing capacity in
2005 and allow us to meet the demand already being shown by
customers this year."
Utilizing proprietary technologies, Bodisen sells over 60
packaged products in 3 product categories: Organic Compound
Fertilizer; Organic Liquid Fertilizer; and Pesticides &
Insecticides. Bodisen's organic fertilizers can be absorbed by
plants within 48 hours while enriching soil conditions without the
damaging effects associated with chemical fertilizers.
About Bodisen Biotech, Inc.
Bodisen is headquartered in Shaanxi, China, an agricultural hub
of China and the economic gateway to the western regions of China.
The Bodisen brand is a highly respected organic brand in China. Its
"green" products support the mandate of the Chinese national
government to increase crop yields for the purpose of decreasing
China's dependency on food imports.
Safe Harbor Statement
This press release may contain forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based
on the current expectations or beliefs of Bodisen Biotech, Inc.
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements.
Bodisen Biotech, Inc.
Source: Bodisen Biotech, Inc.